サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1316285

インフルエンザワクチンの世界市場-2023年～2030年

Global Influenza Vaccines Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
インフルエンザワクチンの世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のインフルエンザワクチン市場は、2022年に64億米ドルに達し、2030年には108億米ドルに達する見通しで、有利な成長が予測されています。世界のインフルエンザワクチン市場は、予測期間中（2023～2030年）にCAGR 6.9%を示すと予測されています。

インフルエンザ（流感）予防接種（インフルエンザ予防注射）は、調査によると、これからのシーズンに最も頻度が高いと予想される4種類のインフルエンザウイルスから身を守るワクチンです。インフルエンザワクチンの大半は、一般的に腕に注射針を刺して接種する「インフルエンザ予防注射」ですが、点鼻薬によるインフルエンザワクチンもあります。インフルエンザ・ワクチンの有効性は、ワクチンと流行株の一致、個人の年齢や健康状態、その他の要因によって、シーズンごとに異なる可能性があります。

市場力学

インフルエンザワクチン接種の増加

米国疾病予防管理センター（Centers for Disease Control and Prevention）の最新ファクトシートによると、2023年3月4日、米国では2022-23年シーズンに向けて1億7,337万回分のインフルエンザワクチン接種が行われました。ワクチン製造業者は、2022-2023年シーズンに1億7350万から1億8350万回分のインフルエンザワクチンを米国に供給すると予測しています。

CDCの全国予防接種調査（National Immunisation Survey-Flu）によると、生後6ヶ月から17歳までの小児のインフルエンザワクチン接種率。2023年4月28日更新データによる2023年4月15日現在の全小児のワクチン接種率（55.1％）は、2022年4月同時期の予測（55.6％）と同じで、2021年4月同時期（57.4％）より2.3ポイント低く、2022年4月同時期の予測（55.6％）より7.1ポイント低いです。

市場企業による新製品開発のための臨床試験の増加

市場参入企業による新製品開発のための臨床試験の増加が、予測期間中の世界のインフルエンザワクチン市場の成長を後押しするとみられます。例えば、2022年5月25日、高度に進化する感染性ウイルスや疾患に対するワクチンの研究を行っているバイオ医薬品企業オシバックスは、開発の初期段階にある主要候補OVX836の臨床開発戦略に関する最新情報を発表しました。

これはオシバックスのT細胞ベースのインフルエンザ候補で、同社独自のオリゴDOMナノ粒子技術プラットフォームを利用して作成され、インフルエンザ株間で高度に保存された内部抗原であるヌクレオプロテイン（NP）に対する免疫反応を誘発することを目的としています。

ワクチン製造の長期化

安全性、品質、有効性の確保に加え、新規ワクチンの開発には通常10年から15年かかる長いプロセスが必要です。長い開発期間の背景には、ワクチン開発の困難さ、臨床開発の世界化、規制要件の違いという3つの主な要因があります。臨床試験の規制要件は国によって大きく異なります。その結果、革新的な予防接種の開発に深刻な遅れが生じる可能性があります。

COVID-19の影響分析

SARS-CoV-2が感染者の呼吸器系に影響を及ぼし、流行期にはインフルエンザワクチン接種の需要が高かったため、COVID-19の流行はパンデミック期のインフルエンザワクチン市場に大きな影響を与えました。このような状況は市場の成長に大きな影響を与え、パンデミック期のインフルエンザワクチン接種需要を押し上げました。コロナウイルスの大流行は、発展途上国、先進国を問わず、世界の定期予防接種プログラムやキャンペーンに影響を与えています。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、この地域の主要市場プレーヤーの数が少ないことから、世界のインフルエンザワクチン市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界のインフルエンザワクチン市場の成長にはほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 政府投資の増加
      • 強力なパイプラインを持つ活発な研究開発投資
    • 抑制要因
      • ワクチンの高コスト
    • 機会
      • 複数の医療機関によって実施されている予防接種プログラムやキャンプ
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 ワクチンタイプ別

  • 4価ワクチン
  • 3価ワクチン

第8章 ウイルスタイプ別

  • A型インフルエンザウイルス
  • B型インフルエンザウイルス

第9章 年齢層別

  • 小児
  • 成人

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東およびアフリカ
    • 主な地域別ダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • AstraZeneca PLC
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • CSL Limited
  • Abbott Laboratories
  • F.Hoffmann-La Roche Ltd
  • Emergent BioSolutions
  • GlaxoSmithKline PLC
  • Gamma Vaccines Pvt. Ltd
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi Pasteur SA

第13章 付録

目次
Product Code: BT598

Market Overview

The global influenza vaccines market reached US$ 6.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 10.8 billion by 2030. The global influenza vaccines market is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

Influenza (flu) vaccinations (flu shots) are vaccines that protect against the four influenza viruses that are expected to be the most frequent during the upcoming season, according to studies. The majority of flu vaccines are "flu shots" administered through the needle, generally in the arm, however, there is also a nasal spray flu vaccine. Influenza vaccination efficacy can vary from season to season, based on factors such as vaccine-to-circulating strain match, individual age and health state, and other factors.

Market Dynamics

Rise in Receiving Influenza Vaccines

The rise in receiving influenza vaccines is one the key driver that helps the market to grow during the forecast period for instance according to the Centers for Disease Control and Prevention updated factsheet On March 4, 2023, 173.37 million doses of flu vaccination had been delivered in the United States for the 2022-23 season. Vaccine producers anticipate supplying the United States with 173.5 million to 183.5 million doses of influenza vaccine for the 2022-2023 season.

Based on the CDC's National Immunisation Survey-Flu, flu vaccine coverage for children aged 6 months to 17 years. As per Data updated on April 28, 2023. Vaccination coverage for all children as of April 15, 2023 (55.1%) is identical to the estimate at the same time in April 2022 (55.6%), 2.3 percentage points lower than the same time in April 2021 (57.4%), and 7.1 percentage points lower than the forecast at the same time in April 2022 (55.6%).

Increasing Clinical Trials For New Product Development By Market Players

Increased clinical trials for new product development by market participants are likely to boost growth in the worldwide influenza vaccines market over the forecast period. For instance, on May 25, 2022, Osivax, a biopharmaceutical firm researching vaccines against highly evolving infectious viruses and disorders, published an update on the clinical development strategy for its main candidate, OVX836, which is still in the early stages of development.

It is Osivax's T-cell-based influenza candidate, which was created utilising the company's proprietary oligoDOM nanoparticle technology platform and is intended to elicit immune responses against the nucleoprotein (NP), a highly conserved internal antigen across flu strains.

Longer Timeline For Vaccine Production

In addition to ensuring its safety, quality, and efficacy, novel vaccine development is a lengthy process that normally takes 10 to 15 years. Long timeframes are driven by three key factors: the difficulties of vaccine development, globalised clinical development, and different regulatory requirements. Clinical trial regulatory requirements vary greatly between nations. As a result, there may be severe delays in the development of innovative vaccinations.

COVID-19 Impact Analysis

The COVID-19 epidemic had a substantial influence influenza vaccine market during the pandemic era because SARS-CoV-2 have been affected the respiratory system of infected patients, and the demand for influenza vaccination was high during the epidemic. Such conditions had a considerable influence on market growth, driving up demand for influenza vaccinations during the pandemic. The coronavirus pandemic has an influence on worldwide regular immunisation programmes and campaigns in both developing and developed nations.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global influenza vaccine market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global influenza vaccine market growth over the forecast period.

Segment Analysis

The global influenza vaccines are segmented based on the vaccine type, virus type, age group and region.

Children from the Age Group Segment Account for 37.9% of the Market Share

The children from the age group segment with around 37.9% are expected to dominate during the forecast period. Children have the largest market share and are likely to expand at the quickest rate throughout the forecast period. The factors that can be linked to higher vaccination doses are given to newborn infants and children to protect them from influenza disease at a young age. WHO and the CDC have devised vaccination strategies such as delivering immunisations at a young age to all children globally because of the large increase in influenza infection and frequency rates in young children, many strategies have been developed to enhance influenza vaccination usage in this age group.

For instance, according to CDC the children who have received influenza vaccine vaccinations as of April 15, 2023, are classified according to their age, as follows: Coverage for children aged 6 months to 4 years is 7.9 percentage points greater than for children aged 5 to 12 years (63.7% vs. 55.8%). Children aged 13 to 17 years old scored 17.0 percentage points higher (63.7% vs. 46.8%). Coverage for children aged 5 to 12 years is 9.0 percentage points greater than for children aged 13 to 17 years (55.8% vs. 46.8%).

Geographical Analysis

North America Accounted for Approximately 38.2% of the Market Share

North America is estimated to hold about 38.2% of the total market share throughout the forecast period, owing to government agencies in the United States concentrating on collaborations to enhance the supply of influenza vaccinations. For example, as part of an inter-agency government effort in the United States, the Centres for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) are collaborating to develop new and better influenza vaccines.

For instance, in Feb 2023, Access to Advanced Health Institute (AAHI) received funding of $9.9 million to develop a nasal spray influenza RNA vaccine through the Medical CBRN Defence Consortium (MCDC) Other Transaction Authority (OTA), the Access to Advanced Health Institute (AAHI) has received financing for a project agreement worth up to $9.9 million to develop a prototype intranasal bivalent influenza RNA vaccine candidate.

Competitive Landscape

The major global players in the influenza vaccines market include: AstraZeneca PLC, CSL Limited, Abbott Laboratories, F.Hoffmann-La Roche Ltd, Emergent BioSolutions, GlaxoSmithKline PLC, Gamma Vaccines Pvt Ltd, Merck & Co, Pfizer Inc, Sanofi Pasteur SA among others.

Why Purchase the Report?

  • To visualize the global influenza vaccines market segmentation based on the vaccine type, virus type, age group and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of influenza vaccines market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global influenza vaccines market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Vaccine Type
  • 3.2. Market snippet By Virus type
  • 3.3. Market Snippet By Age Group
  • 3.4. Market Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Number of Government Investments
      • 4.1.1.2. Robust R&D Investments with A Strong Pipeline
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Vaccines
    • 4.1.3. Opportunity
      • 4.1.3.1. The immunization programs and camps are conducted by several medical organizations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post Covid-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Vaccine Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 7.1.2. Market Attractiveness Index, By Vaccine Type
  • 7.2. Quadrivalent*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Trivalent Vaccines

8. By Virus Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
    • 8.1.2. Market Attractiveness Index, By Virus Type
  • 8.2. Type A Influenza Virus *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Type B Influenza Virus

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. Children*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Adult

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AstraZeneca PLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. CSL Limited
  • 12.3. Abbott Laboratories
  • 12.4. F.Hoffmann-La Roche Ltd
  • 12.5. Emergent BioSolutions
  • 12.6. GlaxoSmithKline PLC
  • 12.7. Gamma Vaccines Pvt. Ltd
  • 12.8. Merck & Co. Inc.
  • 12.9. Pfizer Inc.
  • 12.10. Sanofi Pasteur SA

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us